SEC Form 4 · accession 0001209191-17-038677
KYNTRA BIO, INC. · KYNB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thomas F Kearns Jr.
Director
Period of report
Jun 6, 2017
Accepted (ET)
Jun 8, 2017 · 7:51 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000921299
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 6, 2017 | M | 18,000 | $9.775 | A | 156,564 | D | |
| Common StockF1 | Jun 6, 2017 | S | 18,000 | $28.71 | D | 138,564 | D | |
| Common Stock | holding | — | — | — | 110,000 | I | By Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $9.775 | Jun 6, 2017 | M | 12,000 | D | — | Apr 16, 2023 | Common Stock | 12,000 | 0 | D |
| Stock Option (Right to Buy)F2 | $9.775 | Jun 6, 2017 | M | 6,000 | D | — | Apr 16, 2023 | Common Stock | 6,000 | 0 | D |
| Stock Option (right to Buy)F3 | $28.65 | Jun 7, 2017 | A | 12,000 | A | — | Jun 7, 2027 | Common Stock | 12,000 | 12,000 | D |
Explanation of responses
- F1The shares were sold at prices ranging from $28.275 to $29.25. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F2Fully vested.
- F3The shares subject to the option vest and become exercisable quarterly over one year measured from June 7, 2017.